New infectious diseases arise regularly and present urgent public health threats, as in the recent cases of Zika virus and Ebola virus. Containing these new infectious diseases is a major public health challenge, and point-of-care (POC) diagnostics are a critical tool to aid patient care, resource allocation, and disease containment. However, developing new antibodies for these POC diagnostics can take 16-24 months, which is far too late for newly arising infectious disease crises. Additionally, developing a new antibody diagnostic can cost hundreds of millions of dollars. There is therefore a dire need for strategies that accelerate the development of POC diagnostics. This technology is a novel method for rapidly developing diagnostics from existing antibodies.